Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDCC Regulatory News (DCC)

Share Price Information for DCC (DCC)

Share Price is delayed by 15 minutes
Get Live Data
6,025.00    45.00 (0.75%)
Bid:
6,020.00
Ask:
6,030.00
Spread: 10.00 (0.166%)
Market Cap: £5.15b
DCC Live PriceLast checked at - London Stock Exchange

Intraday DCC Share Chart

Form 38.5A (EPT/RI)-DCC plc Amend

6 May 2026 17:36

RNS Number : 3108D
JPMorgan Securities Plc
06 May 2026
 

Ap34

 

AMENDMENT

 

FORM 38.5(a) (EPT/RI)

 

IRISH TAKEOVER PANEL

 

DEALING DISCLOSURE UNDER RULE 38.5(a) OF THE IRISHTAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022BY A CONNECTED EXEMPT PRINCIPAL TRADER WITHRECOGNISED INTERMEDIARY STATUS AND DEALING INA CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

DCC plc

(c) Name of the party to the offer with which exempt principal trader is connected: (Note 1)

Corporate broker and financial adviser to DCC plc

(d) Date dealing undertaken:

05 May 2026

(e) In addition to the company in 1(b) above, is the exempt principal trader also making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER (Note 2)

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

Ap35

 

(a) Purchases and sales

 

 

Class of relevant security (Note 3)

Purchases/ sales

Totalnumber of securities

Highest price per unit paid/ received

Lowest price per unit paid/ received

€0.25 ordinary shares

Purchase

195,494

58.1486 GBP

56.5625 GBP

Sale

119,862

 

58.0000 GBP

 

56.6000 GBP

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description e.g. CFD

Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities (Note 4)

Price perunit (Note 5)

€0.25 ordinary shares

Equity SWAP

Decrease Long

 

 

 

 

 

 

 

 

 

 

Decrease Short

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Increase Long

 

 

 

 

 

Increase Short

 

 

 

 

 

 

 

 

 

Opening a long position

 

Opening a short position

2,190

 695

 2,161

 73

 41

 76

 2,132

 3,549

 153

 650

 

 1,925

 18,797

 371

 171

 179

 164

 511

 28

 128

 614

 799

 344

 37

 274

 3,829

 22

 1,141

 

 4,218

 149

 828

 2,223

 129

 

 86,958

 634

 1,553

 2,071

 2,360

 200

 1,822

 1,008

 3,468

 

 2,127

 

 2,127

 784

57.0040 GBP

57.0114 GBP

77.6635 GBP

57.0029 GBP

57.0011 GBP

57.0026 GBP

57.1275 GBP

57.2291 GBP

57.1290 GBP

57.1731 GBP

 

57.0258 GBP

57.0000 GBP

57.0539 GBP

57.4443 GBP

57.0175 GBP

57.4900 GBP

57.4525 GBP

57.2430 GBP

57.7590 GBP

57.2337 GBP

57.1449 GBP

57.1970 GBP

57.0494 GBP

57.3180 GBP

57.0279 GBP

57.1408 GBP

57.1409 GBP

 

57.0437 GBP

56.9974 GBP

57.0625 GBP

57.0345 GBP

57.0974 GBP

 

57.0000 GBP

57.0009 GBP

57.0391 GBP

57.2762 GBP

57.7846 GBP

57.4192 GBP

57.1282 GBP

57.5446 GBP

57.4807 GBP

 

57.0000 GBP

 

57.4686 GBP

56.8596 GBP

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates (Note 4)

Exercise price per unit

Type  e.g. American, European etc.

Expirydate

Option money paid/ received per unit

 

 

 

 

 

 

 

 

 

(ii) Exercise

 

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise priceper unit (Note 5)

 

 

 

 

 

 

(d) Other dealings (including transactions in respect of new securities)

 

Class of relevant security

Nature of dealing e.g. subscription, conversion, exercise

Details

Price per unit (if applicable) (Note 5)

 

 

 

 

 

Ap36

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

 

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 None

 

Date of disclosure:

06 May 2026

Contact name:

Hetvi Shah

Telephone number:

44 2034 936359

 

Public disclosures under Rule 38 of the Rules must be made to a Regulatory Information Service.

 

Ap37

 

NOTES ON FORM 38.5(a)

 

1. See the definition of "connected principal trader" in Rule 2.2 of Part A of the Rules.

 

2. See the definition of "dealing" in Rule 2.1 of Part A of the Rules.

 

3. See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.

 

4. See Rule 2.5(d) of Part A of the Rules.

 

5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.

 

6. If details included in a disclosure under Rule 38 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

 

For full details of disclosure requirements, see Rules 8 and 38 of the Rules. If in doubt, consult the Panel.

 

References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ITPEAKSKEDSKEFA
Date   Source Headline
27th Nov 20202:31 pmRNSTotal Voting Rights
18th Nov 202010:05 amRNSEnabling energy transition webcast
17th Nov 202010:16 amRNSDirector/PDMR Shareholding
13th Nov 20203:40 pmRNSDirector/PDMR Shareholding
10th Nov 20207:00 amRNSResults for the six months ended 30 September 2020
4th Nov 20204:35 pmRNSHolding in Company TR-1
29th Oct 20207:15 amRNSDirector Declaration
23rd Oct 20204:30 pmRNSHolding in Company TR-1
23rd Oct 20209:38 amRNSUpcoming Events
19th Oct 20203:51 pmRNSHolding in Company TR-1
14th Oct 20204:16 pmRNSHolding in Company TR-1
6th Oct 20203:40 pmRNSHolding in Company TR-1
5th Oct 202012:29 pmRNSHolding in Company TR-1
5th Oct 20209:30 amRNSHolding in Company TR-1
1st Oct 20205:07 pmRNSHolding in Company TR-1
22nd Sep 20204:29 pmRNSHolding in Company TR-1
21st Sep 20207:00 amRNSDCC expands LPG business in the US and Netherlands
9th Sep 20203:18 pmRNSAppointment of General Counsel & Company Secretary
4th Sep 20204:10 pmRNSUpdate on LTIP Performance Condition Ranges
31st Jul 202012:52 pmRNSTotal Voting Rights
23rd Jul 20204:14 pmRNSHolding in Company TR-1
21st Jul 202011:42 amRNSDirector/PDMR Shareholding
20th Jul 20204:00 pmRNSHolding in Company TR-1
17th Jul 20201:59 pmRNSResult of AGM
17th Jul 20207:00 amRNSInterim Management Statement
14th Jul 20202:28 pmRNSHolding in Company TR-1
8th Jul 202011:38 amRNSHolding in Company TR-1
24th Jun 20209:39 amRNSHolding in Company TR-1
18th Jun 202012:25 pmRNS2020 Annual Report, Notice of AGM and Proxy Form
3rd Jun 202010:10 amRNSHolding in Company TR-1
29th May 202011:27 amRNSTotal Voting Rights
28th May 20206:21 pmRNSDirector/PDMR Shareholding
28th May 20201:02 pmRNSHolding in Company TR-1
19th May 20205:04 pmRNSBoard Changes
19th May 20207:00 amRNSResults for the year ended 31 March 2020
14th May 20203:30 pmRNSHolding in Company TR-1
27th Apr 20206:02 pmRNSDisclosure of Rights Attached to Equity Shares
16th Apr 20204:24 pmRNSDirector Declaration
9th Apr 20204:21 pmRNSHolding in Company TR-1
3rd Apr 20204:01 pmRNSHolding in Company TR-1
25th Mar 20203:22 pmRNSHolding in Company TR-1
25th Mar 20207:00 amRNSDCC Healthcare announces acquisition of Amerilab
19th Mar 20204:10 pmRNSHolding in Company TR-1
19th Mar 20209:46 amRNSHolding in Company TR-1
18th Mar 202012:14 pmRNSHolding in Company TR-1
6th Mar 20204:08 pmRNSHolding in Company TR-1
28th Feb 202010:54 amRNSTotal Voting Rights
24th Feb 20208:38 amRNSBoard Change
24th Feb 20208:34 amRNSChief Financial Officer Succession
12th Feb 20209:10 amRNSHolding in Company TR-1

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.